B
Bull
Bull · 25%CARM
$0.26
Scenario price
$0.154
-0.067 (-43.81%)At close
Loading chart…
- High
- 0.170
- Open
- 0.159
- VWAP
- 0.16
- Vol
- 17.54M
- Mkt Cap
- 53.17M
- Low
- 0.147
- Amount
- 2.75M
- EV/EBITDA, TTM
- 0.00
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
Valuation Metrics
The current forward P/E ratio for Carisma Therapeutics Inc (CARM) is -0.38, compared to its 5-year average forward P/E of -1.34.
Alphio AI Price Scenarios for CARM
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
9.502-18BusinesswireCarmila Reports 2025 Results: Sustained Growth and Innovation
- 7.002-13Businesswire
CARMILA Releases Shareholder Voting Rights Data
- 8.501-12Businesswire
Carmila Updates Liquidity Agreement with Kepler Chevreux, Total Transactions Reach €11.14 Million
9.012-05PRnewswireCarisma Therapeutics Voluntarily Delists from Nasdaq, Ending Reporting Obligations
9.012-05Yahoo FinanceCarisma to Withdraw from Nasdaq and Terminate SEC Registration
CARM FAQ — answered by Alphio AI
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.